| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OS Therapies: OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company | 427 | Newsfile | OST-HER2 remains eligible for Priority Review Voucher ("PRV") if approved by the U.S. Food and Drug Administration's ("FDA") on or before September 30, 2029Company continues to benefit from its UK research... ► Artikel lesen | |
| 12.11. | OS Therapies erhält Mehrwertsteuerrückerstattung und gibt Update zu FDA-Voucher-Programmen | 1 | Investing.com Deutsch | ||
| 12.11. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 10.11. | OS Therapies: OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma | 368 | Newsfile | US Based Clinical Stage Oncology Company Begins Critical Step Following Successful September 2026 Scientific Advice MeetingSubmission expected to be accepted in the fourth quarter of 2026Potential early... ► Artikel lesen | |
| 05.11. | OS Therapies: OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial | 330 | Newsfile | Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K's MHRA for Early Commercial Access and Trial AuthorisationGrasonville, Maryland--(Newsfile Corp. - November 5, 2026)... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 19.10. | OS Therapies Inc - 8-K, Current Report | 3 | SEC Filings | ||
| 19.10. | OS Therapies: OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million | 706 | Newsfile | Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market... ► Artikel lesen | |
| 07.10. | OS Therapies: OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma | 547 | Newsfile | Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc.... ► Artikel lesen | |
| 06.10. | OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| 06.10. | OS Therapies: OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 676 | Newsfile | Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p... ► Artikel lesen | |
| 05.10. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO | 2 | Seeking Alpha | ||
| 01.10. | OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer | 590 | Newsfile | Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic(OST-HER2; daznelimgene lisbac)Grasonville, Maryland--(Newsfile... ► Artikel lesen | |
| 24.09. | OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) | 561 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 21.09. | OS Therapies: OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis | 850 | Newsfile | Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing... ► Artikel lesen | |
| 17.09. | OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program | 858 | Newsfile | FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize... ► Artikel lesen | |
| 15.09. | OS Therapies: OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing | 561 | Newsfile | Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in... ► Artikel lesen | |
| 09.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | OS Therapies Reports Strong Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| 08.09. | OS Therapies: OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 587 | Newsfile | 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,411 | -1,23 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| NOVAVAX | 7,180 | -0,97 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| CRISPR THERAPEUTICS | 36,890 | +0,71 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| PALATIN TECHNOLOGIES | 5,150 | 0,00 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| OCUGEN | 0,668 | -0,89 % | Ocugen: Lizenzdeal mit Celairis - OCU400 bekommt Asien-Pazifik-Schub | ||
| VIVORYON THERAPEUTICS | 0,678 | +0,59 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,289 | +2,12 % | 14 Tage oder 60 Monate Lagerung: Warum Gilead, Mesoblast und NurExone regenerative Therapien unterschiedlich verfügbar machen | ||
| SAREPTA THERAPEUTICS | 13,260 | 0,00 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,800 | +7,63 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| REDHILL BIOPHARMA | 0,350 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 5,100 | +1,15 % | Myriad Genetics auf Stephens-Konferenz: Verstärkter Fokus auf Onkologie | ||
| MANNKIND | 3,687 | 0,00 % | MannKind auf der Jefferies Global Healthcare Conference: Wachstumstreiber formieren sich - Profitabilität für Q4 2026 im Visier | ||
| IMMUNIC | 7,034 | +3,14 % | EQS-News: Immunic AG: Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
13.11.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,720 | -0,01 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Highlighting Phio's Differentiated, Paradigm-Shifting Treatment Approach for Skin CancerLive Presentation and Q&A: Wednesday, November 18, 2026 2 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp.... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,120 | +6,37 % | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen |